Graft Polymer (UK) PLC hailed the progress made since its initial public offering in January as it reported final results for 2021.
“This has been a period of growth for us, particularly since listing [in January], with a number of milestones reached,” Victor Bolduev, chief executive, said.
The developer of polymer modification, biological supplements and nano-drug delivery systems achieved positive cash flow via organic growth at its research and development in Slovenia.
Pre-payments on tailor-made equipment, which are expected to be delivered in the coming weeks, will double the company’s production capacities, it said.
It also was granted several patents, enhancing Graft’s reach as well as protecting IP and industry position, and a HAACP certificate allowing it to enter the business-to-consumer market further expanding its customer reach.
"With all of this and more occurring within the first few months of trading, Graft Polymer have a very exciting period ahead and we look forward to updating you on the company's progress," Bolduev added.